John E. Bishop - 27 Feb 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Reporting relationship: Chief Technology Officer
Issuer ticker: LYRA
Reported as of: 27 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2023, 15:10:19 UTC
Prior SEC filing: 14 Oct 2022
Next SEC filing: 01 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Jason Cavalier, Attorney-in-Fact for John E. Bishop

Key filing fact

John E. Bishop filed Form 4 for Lyra Therapeutics, Inc. (LYRA) on 28 Feb 2023.

Key facts

This page summarizes John E. Bishop's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2023, 15:10.

Change

Previous filing in this sequence was filed on 14 Oct 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYRA transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +220,000
Change %
Price: $0.000000
Shares after: 220,000
Date: 27 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220,000
Exercise price: $2.31
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests and becomes exercisable as to 25% of the underlying shares on February 27, 2024 and in 36 substantially equal monthly installments thereafter.